Quantcast

Latest Nonbenzodiazepine Stories

2012-07-12 23:00:33

Even moderate use of sleeping pills carries potential long-term risks. Dr. Dan Naim, a sleep specialist, recommends a non-drug route for treating insomnia. Los Angeles, CA (PRWEB) July 12, 2012 Early death is one of the risks associated with sleeping pills, according to a new study. While up to 10 percent of adults in the U.S. take some form of sleep aid medication, Dr. Dan Naim of Los Angeles Sleep Study Institute recommends sleeping pills only after non-drug routes are exhausted and for...

2012-04-23 03:13:35

Tokyo, Apr 17, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the insomnia treatment Lunesta(R) (eszopiclone) in Japan on April 18.Lunesta, originally discovered and developed by Sunovion Pharmaceuticals Inc. ("Sunovion"; formerly Sepracor Inc.; currently a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd.), is the first non-benzodiazepine type GABAA agonist to be launched in Japan in 12 years, and is believed to enhance GABA activity while exerting hypnotic...

2012-01-18 04:20:01

Tokyo, Jan 18, 2012 - (JCN Newswire) - Eisai Co. Ltd announced today that it received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) on January 18, 2012 to market Lunesta (eszopiclone), a product the company has been developing in Japan, as a treatment for insomnia.Lunesta, originally discovered and developed by Sunovion Pharmaceuticals Inc. ("Sunovion"; formerly Sepracor Inc., "Sepracor"; a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd), has been marketed in the...

2010-11-08 14:54:26

When sleep doesn't come easily, some people turn to what they think is an easy solution "“ sleeping pills. But according to a Baylor College of Medicine sleep expert, sleep medications "“ whether prescription or over-the-counter "“ shouldn't be taken lightly. "All medications have side effects that need to be weighed whenever you take them," cautioned Dr. Phil Alapat, assistant professor of pulmonary, critical care and sleep medicine at BCM and medical director of the BCM...

2010-07-12 07:00:00

MOUNTAIN VIEW, Calif., July 12 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has selected AZ-007 (Staccato zaleplon) for the treatment of insomnia as the next product candidate to move forward into active development. This decision follows an Alexza technology and portfolio review during the first half of 2010. In addition, Alexza has created Addicere Therapeutics, Inc., a wholly-owned subsidiary, to develop all applications of the...

2009-01-16 12:32:00

ANN ARBOR, Mich., Jan. 16 /PRNewswire/ -- Use of prescription sleep aids nearly tripled among 18- to 24-year-olds between 1998 and 2006, according to a study released today by the Healthcare business of Thomson Reuters. During the study period, the average length of time sleep aids were used by adults under age 45 increased more than 40 percent -- rising from 64 days in 1998 to 93 days in 2006. "Insomnia, a condition traditionally associated with older adults, appears to be...

fa1ba12e98af16b03725744acd26cf5d1
2009-01-16 06:55:00

Need the help of a pill to catch some zzz's? According to a new study you're not alone; the use of prescription sleep aids nearly tripled among young adults between 1998 and 2006."Insomnia, a condition traditionally associated with older adults, appears to be causing larger numbers of young adults to turn to prescription sleep aids, and to depend on them for longer periods of time," said William Marder, senior vice president and general manager for the healthcare business of Thomson Reuters,...

2008-09-26 12:00:35

LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. today announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously announced promising data from its 8-week, placebo controlled, double-blind, multi-center Phase II trial in patients with persistent stuttering which showed that pagoclone produced a statistically significant benefit in...

2008-09-18 18:00:19

NovaDel Pharma Inc. (AMEX: NVD) today announced that the U.S. Food and Drug Administration (FDA) has requested an extension of up to 3 months on the Prescription Drug User Fee Act (PDUFA) deadline in order to complete the review of the Company's Zolpimist (zolpidem tartrate) Oral Spray for the short-term treatment of insomnia. Based on the original PDUFA date for Zolpimist, the FDA will reply on or before December 19, 2008. "We believe we have submitted a high quality 505(b)(2) application...

2006-06-27 16:20:00

NEW YORK (Reuters Health) - Cognitive behavioral therapy (CBT), a counseling method that emphasizes the role of thinking and behavior modification, is more effective than zopiclone for the short- and long-term treatment of chronic insomnia in older adults, according to a new report. In fact, the study found that zopiclone was no more effect for insomnia than placebo was (a sugar pill.) Zopiclone, sold under the trade name Imovane, is a central nervous system depressant. To prevent excessive...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'